Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Milgrom, A. Fowler Taylor, M. Blogg, C. Fernandez Vidaurre (Denver, East Hanover, United States Of America; Horsham, United Kingdom). Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab. Eur Respir J 2010; 36: Suppl. 54, 2642

Member's Comments

No comment yet.

Related content which might interest you: Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 The role of omalizumab or rhuMAb-E25 in the treatment of allergic rhinitis Source: Eur Respir J 2004; 24: 330 Year: 2004 Does treatment of allergic rhinitis with intranasal steroids improve asthma control Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Intranasal and inhaled corticosteroids in allergic rhinitis and asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Safety and efficacy of omalizumab in children with allergic asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Omalizumab, a novel therapy for severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001 Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006 To assess the effects of combined nasal and inhaled corticosteroid in patients with asthma and persistent allergic rhinitis Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Omalizumab therapy of the children with uncontolled atopic bronchial asthma (BA) Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2010 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012